Acute hepatic porphyria (AHP) is a group of rare genetic disorders that cause the liver to produce toxic levels of certain chemical byproducts, leading to severe attacks of abdominal pain, neurological dysfunction, and psychiatric symptoms. It affects roughly 5 in 100,000 people worldwide, though many more carry the gene mutations without ever experiencing symptoms.
How AHP Disrupts the Body
Your body constantly produces heme, a molecule essential for carrying oxygen in the blood. Making heme requires an eight-step assembly line of enzymes in the liver. In AHP, one of those enzymes is deficient due to an inherited gene mutation. When the body tries to ramp up heme production, the steps before that broken enzyme become a bottleneck, and two intermediate chemicals, called ALA and PBG, build up and spill into the bloodstream.
These chemicals are toxic to nerve tissue. ALA interferes with signaling between nerve cells, damages the protective coating around nerves in the brain and spinal cord, compromises energy production inside cells, and causes blood vessels to constrict. This widespread nerve damage explains why AHP produces such a puzzling mix of symptoms, from gut pain to seizures to psychiatric disturbances.
The Four Types
Three of the four types follow an autosomal dominant inheritance pattern, meaning you only need one copy of the mutated gene (from one parent) to be at risk. These are acute intermittent porphyria (AIP, the most common), variegate porphyria, and hereditary coproporphyria. The fourth type, ALA dehydratase deficiency porphyria, is autosomal recessive and extremely rare.
A striking feature of AHP is its remarkably low penetrance. About 1 in 1,700 people of European descent carry the AIP gene mutation, yet only around 1% of those carriers ever have an acute attack. The rest are “latent heterozygotes” who may never know they carry the gene. What separates symptomatic patients from silent carriers isn’t fully understood, but environmental triggers play a major role.
What Triggers an Attack
Acute attacks rarely come out of nowhere. They’re typically set off by factors that increase the body’s demand for heme, which forces the broken pathway to work harder and produce more toxic buildup. The most well-established triggers include fasting or restrictive dieting, certain medications (particularly barbiturates, sulfonamides, and some seizure drugs), hormonal changes (especially progesterone fluctuations during the menstrual cycle or from hormonal contraceptives), alcohol use, and physical or emotional stress.
This is why identifying silent carriers matters. Even people who have never had an attack benefit from knowing their status so they can avoid porphyria-triggering medications and lifestyle factors.
What an Attack Feels Like
The hallmark symptom is severe abdominal pain that seems disproportionate to what a physical exam reveals. The belly is intensely painful, but there’s no obvious surgical cause, no tenderness in a specific spot, and imaging often looks normal. This mismatch frequently leads to misdiagnosis or unnecessary surgery. Nausea and vomiting commonly accompany the pain.
Beyond the gut, attacks affect the autonomic nervous system, causing a rapid heart rate and dangerous spikes in blood pressure. Pain can radiate into the back, chest, and limbs. As attacks progress in severity, they can involve motor neuropathy, with progressive muscle weakness that in the worst cases leads to paralysis of all four limbs. Sensory loss and numbness also occur.
Psychiatric and neurological symptoms round out what’s described as the “classic triad” of AHP: abdominal pain, peripheral neuropathy, and central nervous system disturbances. Some people experience anxiety, confusion, hallucinations, or frank psychosis during attacks. Seizures and loss of consciousness can occur in the most severe episodes. Variegate porphyria and hereditary coproporphyria may also produce a sun-sensitive blistering skin rash, though the other two types do not.
A typical attack lasts one to two weeks. Some patients experience isolated episodes separated by years, while others have recurrent attacks, sometimes monthly in sync with the menstrual cycle.
How It’s Diagnosed
The key diagnostic test is a urine sample measuring levels of ALA and PBG. During an acute attack, these levels spike dramatically. Researchers have established that normal PBG levels fall below 0.137 mmol/mol creatinine and normal ALA levels below 1.47 mmol/mol creatinine. Values above these thresholds, particularly PBG levels elevated several-fold, strongly point to AHP. The test is most reliable when collected during or shortly after symptoms begin, because levels can drop between attacks.
Once elevated levels confirm AHP, genetic testing identifies which specific enzyme is affected and which type of porphyria a person has. This also allows family screening to identify silent carriers.
Treating Acute Attacks
For mild attacks, the initial approach focuses on removing triggers and ensuring adequate carbohydrate intake, since glucose helps suppress the overactive heme production pathway. For severe attacks, intravenous heme therapy is the most effective treatment. It works by delivering ready-made heme directly into the bloodstream, which signals the liver to dial down the enzyme that drives the whole pathway. This rapidly reduces the toxic buildup of ALA and PBG. A course of treatment typically runs three to five days, and most attacks resolve within that window.
Preventing Recurrent Attacks
For patients who experience frequent attacks, a newer therapy called givosiran (brand name Givlaari) represents a significant shift in management. It’s a monthly injection that works through RNA interference, essentially silencing the gene for the enzyme that kicks off heme production in the liver. By keeping that first step quiet, the toxic intermediates never accumulate in the first place. This reduces circulating ALA and PBG levels on an ongoing basis rather than just treating attacks after they start.
Lifestyle management remains important regardless of treatment. Avoiding known triggers, maintaining regular meals, being cautious with new medications, and working with a specialist to manage hormonal factors all help reduce attack frequency.
Long-Term Health Risks
AHP isn’t just about acute attacks. People with a history of active disease face significantly elevated risks of liver cancer. A large matched cohort study found that 6.7% of AHP patients developed primary liver cancer during follow-up, compared to just 0.2% of the general population, a roughly 38-fold increase in risk. The danger is highest in patients over 50 who have a history of elevated PBG levels, with an annual liver cancer incidence of about 1.8%. This is why regular liver surveillance with imaging is recommended for AHP patients, particularly as they age.
Kidney function can also decline over time in patients with chronic disease activity, likely related to the ongoing toxic effects of ALA on kidney tissue. Monitoring kidney health is a standard part of long-term AHP care.